Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 13/20 | 0.50 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP3 | P08254 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MMP12 | P39900 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | MMP14 | P50281 | 1/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6524383 | 0.93 | PTGDR2 (0.59) | PTGDR2MMP1MMP2MMP3MMP9 | |
| SCHEMBL6524890 | 0.89 | PTGDR2 (0.61) | PTGDR2MMP1MMP2MMP3MMP9 | |
| SCHEMBL3395183 | 0.81 | PTGDR2 (0.68) | PTGDR2MMP1MMP2MMP3MMP9 | |
| SCHEMBL2277554 | 0.78 | PTGDR2 (0.75) | PTGDR2 | |
| SCHEMBL2272115 | 0.74 | PTGDR2 (0.81) | PTGDR2 | |
| SCHEMBL2272170 | 0.74 | PTGDR2 (0.70) | PTGDR2 | |
| SCHEMBL1466236 | 0.72 | PTGDR2 (0.76) | PTGDR2 | |
| SCHEMBL1190574 | 0.71 | PTGDR2 (0.53) | PTGDR2 | |
| SCHEMBL1466737 | 0.70 | PTGDR2 (0.94) | PTGDR2 | |
| SCHEMBL3969463 | 0.69 | PTGDR2 (0.47) | PTGDR2MMP1MMP2MMP3MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110060026-A1 | Indoles Active on CRTH2 Receptor | PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) | 2011-03-10 | — | — | US | disclosed |
| EP-2245010-A1 | INDOLES ACTIVE ON CRTH2 RECEPTOR | Pulmagen Therapeutics (Asthma) Limited (GB) | 2010-11-03 | — | — | EP | disclosed |
| WO-2009090399-A1 | INDOLES ACTIVE ON CRTH2 RECEPTOR | ARGENTA DISCOVERY LIMITED (GB) | 2009-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110060026-A1 | Indoles Active on CRTH2 Receptor | ARRB1, GPR3, HRH3 | PTGDR2 173/4885MMP1 3549/4885MMP2 4461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.